浙江东亚药业股份有限公司监事会关于公司2024年限制性股票 激励计划激励对象名单的公示情况说明及核查意见的公告

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. has approved the 2024 Restricted Stock Incentive Plan and has publicly disclosed the names and positions of the proposed incentive recipients [1][2]. Disclosure Details - The public disclosure includes the names and positions of the proposed incentive recipients [2]. - The disclosure period is from October 31, 2024, to November 9, 2024 [1]. - The disclosure method includes posting on the Shanghai Stock Exchange website and internal announcements [1]. - Employees can provide feedback through phone, email, or written communication during the disclosure period [1]. Verification Process - The supervisory board has verified the list of proposed incentive recipients, including their identification documents and employment contracts [2]. - The verification confirms that the basic information of the proposed recipients is accurate and does not contain any false or misleading statements [2][4]. Supervisory Board's Opinion - The supervisory board states that all proposed incentive recipients are current employees in relevant positions at the time of the announcement [2]. - None of the proposed recipients have been deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission in the past 12 months [2]. - The proposed recipients do not fall under any disqualifying conditions as per the Company Law and relevant regulations [2][3]. Compliance with Regulations - All individuals included in the incentive plan meet the legal and regulatory requirements as well as the conditions specified in the incentive plan draft [4].